A Milestone

Abstract

Get full access to this article

View all access options for this article.

References

Hamburg

. Remarks at the National Press Club Speaker Luncheon, October 6, 2010.

FDA. Advancing regulatory science at FDA: a strategic plan. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/RegulatoryScience/UCM268225.pdf. Published August 2011. Accessed April 5, 2018.

European Medicines Agency. http://www.ema.europa.eu/ema/. Accessed April 5, 2018.

Pharmaceuticals and Medical Devices Agency. https://www.pmda.go.jp/english/ Accessed April 5, 2018.

Meyer

. The role of academic medical centers in advancing regulatory science. Clin Pharmacol Ther. 2014;95:471–473.

Goldman

Seigneuret

Eichler

. The Innovative Medicines Initiative: an engine for regulatory science. Nat Rev Drug Discov. 2015;14:1–2.

Woodcock

. Paving the critical path of drug development: the CDER perspective. Nat Rev Drug Discov. 2014;13:783–784.

Hong

Slikker

Jr . Advancing translation of biomarkers into regulatory science. Biomark Med. 2015;9:1043–1046.

Grillo

Huang

. Perspectives in regulatory science: translational and clinical pharmacology. Drug Discov Today Technol. 2016;21 /22:67–73.

10.

Klein

Wang

Feagan

Omoto

. Biosimilars: state of clinical and regulatory science. J Pharm Pharm Sci. 2017;20:332–348.

11.

Kurz

. Advancing regulatory science, advancing regulatory practice. Pharmacoepidemiol Drug Saf. 2017;26:722–726.

12.

Tan-Koi

Leow

Teo

. Applications of pharmacogenomics in regulatory science: a product life cycle review [published online ahead of print December 5, 2017]. Pharmacogenomics J.